Maykin Ho's Insider Trades & SAST Disclosures
Maykin Ho's most recent trade in Neumora Therapeutics Inc. was a trade of 95,586 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Maykin Ho.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neumora Therapeutics Inc. | Maykin Ho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 95,586 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 95,586 | 95,586 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 28,571 | 28,571 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Maykin Ho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 28,571 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 27,802 | 27,802 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Maykin Ho | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 27,802 | 0 | - | - | Stock Option (Right to Buy) | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Neumora Therapeutics Inc. | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 28,571 | 28,571 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 20,100 | 20,100 | - | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 14,912 (0%) | 0% | 0 | Common stock | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Biomarin Pharmaceutical In... | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,720 | 21,360 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 11,524 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 12,666 | 12,666 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 8,289 | 40,021 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Maykin Ho | Director | Sale of securities on an exchange or to another person at price $ 17.68 per share. | 07 Jun 2023 | 6,225 | 31,501 (0%) | 0% | 17.7 | 110,058 | Common Stock |
| FibroGen Inc | Maykin Ho | Director | Sale of securities on an exchange or to another person at price $ 16.79 per share. | 07 Jun 2023 | 2,295 | 37,726 (0%) | 0% | 16.8 | 38,533 | Common Stock |
| Biomarin Pharmaceutical In... | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 4,190 | 16,640 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 25,684 | 25,684 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,777 | 31,732 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 4,980 | 12,450 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 6,549 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 4,964 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 4,700 | 15,955 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 5,120 | 7,470 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit | |
| Biomarin Pharmaceutical In... | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 2,350 | 2,350 (0%) | 0% | 0 | Common Stock | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 7,800 | 7,800 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2020 | 4,700 | 11,255 (0%) | 0% | 0 | Common Stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 8,096 | 8,096 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 1,878 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2020 | 1,878 | 3,278 (0%) | 0% | - | Common stock | |
| Agios Pharmaceuticals Inc | Maykin Ho | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 1,686 | 1,686 | - | - | Restricted stock units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges